Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Business

CVS Health to pull decongestants with phenylephrine off shelves

by October 20, 2023
October 20, 2023
CVS Health to pull decongestants with phenylephrine off shelves

U.S. pharmacy chain CVS Health said on Thursday it is pulling some of the most common decongestants with phenylephrine as the only active ingredient from its shelves and will no longer sell them.

The move comes after a panel of advisers to U.S. health regulators raised doubts over the efficacy of the ingredient.

Last month, the panel refused to back the effectiveness of oral over-the-counter (OTC) medicines made with phenylephrine, adding that no more trials were required to prove otherwise.

CVS said “other oral cough and cold products will continue to be offered to meet consumer needs.”

Phenylephrine was substituted for pseudoephedrine in many non-prescription cold and allergy medicines after the latter was restricted amid reports of abuse.

Phenylephrine is a major component used in some of popular products like Benadryl, Sudafed, GSK’s Advil and Kenvue’s Tylenol.

This post appeared first on NBC NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Tesla Stock Has High Expectations: A Strong Pop or Plunge
next post
Mortgage demand falls to the lowest level since 1995 as interest rates near 8%

Related Posts

The FAFSA form error that would have limited...

January 25, 2024

Several Buy Buy Baby and Harmon stores to...

August 19, 2023

Forever 21 seeks rent concessions as fast-fashion brand...

June 24, 2024

Government workers dismayed by Trump’s return-to-office mandate

January 27, 2025

Cash App owner Block pays $40 million in...

April 12, 2025

The U.S. added 199,000 jobs in November and...

December 9, 2023

Dick’s Sporting Goods to buy struggling Foot Locker...

May 16, 2025

Nvidia’s CEO did a Q&A with analysts. What...

March 24, 2025

McDonald’s plans to eliminate self-service soda stations at...

September 13, 2023

Apple has survived Trump’s tariffs so far. It...

September 5, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

    • Lahontan Selects RESPEC and Kappes Cassiday to Update Santa Fe Mineral Resource Estimate and PEA

    • Cartier Discovers Multiple Shallow High-Grade Gold Zones at Cadillac; Cuts 54.6 g/t Au over 1.0 m and 4.4 g/t Au over 6.0 m; Extends North Contact Zone 500 Meters East on Strike

    • Nextech3D.ai’s Krafty Lab Signs New Multinational “Tier 1” Enterprise Agreement and Expands Global In-Person Enterprise Event Delivery

    • Tartisan Nickel Corp. Intersects 10.7 Metres of 1.58% Ni, 0.79% Cu Including 5.0 Metres of 3.02% Ni, 1.48% Cu at the Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario

    • Auto Finance Veteran and Former Tesla National Lease Partner Launches AmeriTrust Financial to Fill Used-Car Leasing Gap

    Categories

    • Business (1,429)
    • Investing (3,463)
    • Politics (3,699)
    • Stocks (1,931)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 moneycontrolplace.com | All Rights Reserved